April 3rd 2024
This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.
Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease
Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.
Read More